https://www.selleckchem.com/products/abt-199.html
With point of care testing (POCT) for infliximab (IFX), ultraproactive therapeutic drug monitoring (TDM) with ad-hoc dose optimisation is possible in patients with inflammatory bowel disease (IBD). To compare the clinical outcomes of an ultraproactive TDM algorithm of IFX based on POCT with reactive TDM in patients with IBD, in a pragmatic clinical trial. All patients with IBD and maintenance IFX treatment were included between June and August 2018 in two centers. Center A applied an ultra-proactive TDM algorithm incorporating POCT, whi
Like
Comment
Share
